Data acquisition of health analytics company Aetion has been finalized by Datavant, significantly expanding Datavant's capabilities in the realm of real-world data analysis and outcomes research.

In a significant move for the healthcare and life sciences industry, Datavant, a leading data technology company, has announced the acquisition of Aetion. The transaction marks the beginning of a new chapter for both entities, as they join forces to create a comprehensive platform for data analysis.

Kyle Armbrester, the CEO of Datavant, welcomed the Aetion team to the company. The acquisition allows Datavant to offer a platform that aims to help healthcare and life sciences companies address research questions about the clinical impact of therapies.

The combined companies will work together to leverage their complementary capabilities, aiming to create a bridge between different datasets. This integrated platform will utilise insights from various sources such as electronic health records, claims data, specialty pharmacy, registries, imaging, lab results, and social determinants of health.

Travis May, the CEO of Datavant, and Mike Tafelski, the CEO of Aetion, led the transaction on the day of the deal. Both companies share a mission to make real-world evidence actionable, and this partnership is a significant step towards achieving that goal.

With over 300 data partners combined, Datavant and Aetion aim to transform the way data is utilised across the drug development continuum. The platform will help healthcare and life sciences companies to better understand the clinical impact of therapies, ultimately improving patient outcomes.

Aetion is now part of Datavant's Life Sciences division, and Kyle Armbrester expressed his excitement about the potential of the combined entities. He stated, "We are thrilled to welcome Aetion to the Datavant family. Together, we will work to make real-world evidence actionable and help our clients address critical research questions about the clinical impact of therapies."

This acquisition is expected to have a significant impact on the healthcare and life sciences industry, as it will provide a platform for data analysis that is unparalleled in its scope and depth. The combined entities will work together to help create a comprehensive platform for data analysis, ultimately enabling healthcare and life sciences companies to make more informed decisions about the therapies they develop and bring to market.

Data acquisition of health analytics company Aetion has been finalized by Datavant, significantly expanding Datavant's capabilities in the realm of real-world data analysis and outcomes research.